The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.

摘要: Background Patients with bipolar disorder (BD) and major depressive (MDD) experience adult attention-deficit/hyperactivity (ADHD) at rates substantially greater than the general population. Nonetheless, ADHD frequently goes untreated in this Methods We reviewed literature regarding management of patients mood disorders. Because a limited number studies have been conducted adults, our treatment recommendations also are partly informed by research children adolescents BD+ADHD or MDD+ADHD, adults ADHD, clinical experience. Results In individuals disorders, is best diagnosed when typical symptoms persist during periods sustained euthymia. Individuals BD+ADHD, particularly those I (BD I), risk for destabilization many treatments, should be prescribed mood-stabilizing medications before initiating therapies. Bupropion reasonable first-line while mixed amphetamine salts methylphenidate may considered determined to low manic switch. Modafinil cognitive-behavioral therapy (CBT) second-line choices. MDD+ADHD moderate severe depression, MDD priority, whereas mildly depressed euthymic order reversed. First-line treatments include bupropion, an antidepressant plus long-acting stimulant, CBT. Desipramine, nortriptyline, venlafaxine options. Conclusions Clinicians vigilant screening comorbid patients. can respond appropriately chosen treatments.